Amortization expense for each of the three-month and six-month periods ended February 28, 2019 and 2018 was $89,375 and $178,750, respectively.
Amortization expense for the three months and six months period ended February 28, 2019 was $1,250 and $2,500, respectively.
Amortization expense for each of the three-month periods ended February 28, 2019 and 2018 was $150,000, and $300,000 for each of the six-month periods ended February 28, 2019 and 2018.
Amortization expense for each of the three-month periods ended February 28, 2019 and 2018 was $1,875 and was $3,750 for each of the six-month periods ended February 28, 2019, and 2018.
Total amortization expense for intellectual property agreements for the three months ended February 28, 2019 and 2018 was $232,292 and $231,042, respectively, and total amortization expense for the six months ended February 28, 2019 and 2018 was $464,583 and $462,083 respectively.
Prior to this lease DILIsym was on a month-to-month rental.
Rent expense, including common area maintenance fees for the three months ended February 28, 2019, and 2018 was $144,763 and $142,459, respectively, and $288,775 and $279,488 for the six months ended February 28, 2019 and 2018, respectively.
On June 1, 2017, as part of the acquisition of DILIsym Services, Inc. the Company acquired certain developed technologies associated with the drug induced liver disease (DILI).
Our contributions to this Plan amounted to $91,999 and $71,045 for the three months ended February 28, 2019 and 2018, respectively and $178,938 and $142,426 for the six months ended February 28, 2019 and 2018 respectively.Labor-related cost increased by $220,000, a combination of increased labor count, and salary increases.
This $21,000 difference primarily reflects foreign currency exchange loss.
Income from operations increased $313,000 or 13.0% in 2QFY19 compared to 2QFY18.
During the period direct contract costs decreased by approximately $71,000.
In 2QFY19 we incurred approximately $1,299,000 of research and development costs, of this amount, $575,000 was capitalized and $724,000 was expensed.
Total research and development cost increased $201,000 in 6moFY19 compared to 6moFY18.
Overall gross margin as a percentage of revenue decreased by 0.8% to 72.5% in 6moFY19 from 73.3% in 6moFY18.
Overall gross margin as a percentage of revenue increased by 2.7% to 73.9% in 2QFY19 from 71.2% in 2QFY18.